Hangzhou Ruomaixing Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the safety and tolerability of single and multiple escalating doses of RMX1001 in healthy Chinese adult subjects Secondary objectives: 1) To determine the major metabolites in human plasma; 2) To evaluate the pharmacokinetic characteristics of RMX1001 and its major metabolites after single and multiple oral administration of different doses of RMX1001 in healthy Chinese adult subjects;

Primary objective: To evaluate the safety and tolerability of RMX1002 after a single oral administration of different doses of RMX1002 to healthy Chinese adult subjects, and to recommend a dose range for later clinical studies. Secondary objective: To evaluate the pharmacokinetic characteristics of RMX1002 after a single oral administration of different doses of RMX1002 to healthy Chinese adult subjects.